Capsulin™ OAD (oral
anti-diabetic)
Primary Indication
|
Treatment of Type 2 diabetes
mellitus
|
Stage of Development
|
Phase IIb in completion
|
- Diabetology has identified classes of compounds that appear to facilitate insulin
absorption in the small intestine adequately to meet clinical and commercial objectives, and that are already used for completely different purposes as excipients in pharmaceutical
formulations
- Use of such agents in its third-generation Axcess™ delivery technology thereby
obviates one major aspect of regulatory risk - the risk of toxicity with novel facilitator agents or carriers - while also potentially reducing development timelines by eliminating the need for
certain preparatory toxicology studies
- Use of such agents for oral peptide delivery is novel and, the Company believes,
patentable; the Company has exclusive licenses in the field of diabetes to a series of patent applications covering Axcess delivery technology
- Potentially improving glycaemic control through optimal physiological delivery
route
- Also, potentially improving compliance
- Finally, the Company believes that its readily available facilitator compounds may
endow it with advantages over competing oral insulin delivery systems that seek to employ new chemical entities
Capsulin™ IR (insulin replacement)
Primary Indication
|
Treatment of Type 1 diabetes
mellitus
|
Stage of Development
|
Phase II
|
- As an alternative to inhaled/injected insulin, Capsulin™ IR will effectively deliver
insulin orally to those with Type 1 diabetes and late stage Type 2, where they are dependent on insulin supplementation
- Reducing the need for injections and/or inhaler equipment
- Potentially improving glycaemic control through optimal physiological delivery
route
- Improving compliance